Editpep — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Editpep is a private, pre-clinical stage biotech developing a novel non-viral delivery platform, PERC™, for CRISPR gene editing in vivo. The platform, exclusively licensed from UC Berkeley, is engineered for high-efficiency editing in hard-to-treat tissues like the brain, with advantages in safety, scalability, and cargo flexibility. The company is leveraging its technology to build a pipeline of CNS-targeted therapies and is actively seeking partnerships to expand its reach into other therapeutic areas.

Neurological DisordersGenetic Diseases

Technology Platform

PERC™ (Peptide-enabled RNP delivery of CRISPR): A non-viral platform that delivers CRISPR as a functionalized ribonucleoprotein complex using engineered peptides for cellular uptake and endosomal escape. Designed for high-efficiency, transient editing in vivo, starting in the central nervous system.

Opportunities

The primary opportunity is to address the vast unmet need in genetic neurological diseases by solving the critical delivery challenge, potentially enabling first-in-class CRISPR therapies for the brain.

The cargo-agnostic, scalable platform also allows for expansion into other tissue types and genetic diseases beyond the CNS, and creates potential for lucrative platform licensing partnerships.

Risk Factors

Key risks include the pre-clinical nature of the technology, which must still prove safe and effective in human trials, and the intense competition in the non-viral CRISPR delivery space.

The company also faces significant financial risk as a pre-revenue entity dependent on raising capital to fund expensive clinical development.

Competitive Landscape

Editpep competes in the non-viral CRISPR delivery space against companies using lipid nanoparticles (e.g., Intellia, Beam), virus-like particles, and other peptide or polymer-based systems. Its specific focus on CNS delivery pits it against other biotechs targeting neurological diseases with gene editing, though its peptide-RNP approach is a differentiating technical strategy.

More companies in Proteomics & Protein Engineering →More companies in United States →